News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘LungCancer’ clear

  • Investigators at Dana-Farber led by Leena Gandhi, MD, PhD, report a promising way of predicting which patients with non-small cell lung cancer (NSCLC) are most likely to benefit from a drug that frees up an immune system attack on tumor cells.

Tags: LungCancer, Immunotherapy

  • Dana-Farber researchers have found that a combination of two already-in-use drugs may have an effect on stopping the growth of the most common genetic subtype of lung cancer setting the stage for clinical trials.

Tags: LungCancer, TargetedTherapy

  • Cancer death rates in the United States continue to decline, according to the Annual Report to the Nation on the Status of Cancer, published online by the journal Cancer.

Tags: BreastCancer, ColonCancer, LungCancer, Prevention

  • Scientists at Dana-Farber Cancer Institute and the University of Colorado Cancer Center report on a gene fusion that spurs the cells to divide rapidly. Treating the cells with a compound that blocks the protein caused the cells to die which may offer a targeted therapy in patients.

Tags: BasicResearch, LungCancer

  • Dana-Farber researchers reported that patients with non-small cell lung cancer (NSCLC) whose tumor cells harbored an abnormal ALK gene responded better to targeted therapy than traditional chemotherapy.

Tags: LungCancer, TargetedTherapy

  • A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.

Tags: LungCancer, TargetedTherapy, Genetics

  • Bruce Johnson, MD, the director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, sorts out the facts about lung cancer and offers simple ways to reduce risk.

Tags: LungCancer, Smoking, TargetedTherapy, Genetics

  • The Cancer Genome Atlas Research Network has identified a large number and variety of DNA alterations in squamous cell lung cancer tumors, which could serve as potential therapeutic targets for treating the second most common type of lung cancer.

Tags: Genomics, LungCancer, TargetedTherapy

  • Dana-Farber researchers report a novel compound has become the first targeted therapy to benefit patients with non-small cell lung cancer.

Tags: LungCancer, TargetedTherapy

  • Adding Avastin to standard chemotherapy treatment may not improve survival rates for people with non-small cell lung cancer aged 65 plus, according to Dana-Farber researchers, who further suggest that clinicians exercise caution in including the drug in treatment recommendations.

Tags: chemotherapy, LungCancer

Showing 1-10 of 25 items